SCHEMBL23930858

SCHEMBL23930858

C=Cc1nc(Br)c(C(=O)OC)n1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.34
CYP1A2 P05177 1/20 0.32
CYP2C19 P33261 1/20 0.32
KDM4E B2RXH2 1/20 0.31
DAPK3 O43293 1/20 0.31
JAK2 O60674 1/20 0.31
PRKD3 O94806 1/20 0.31
MAP4K4 O95819 1/20 0.31
ABL1 P00519 1/20 0.31
CSF1R P07333 1/20 0.31
RET P07949 1/20 0.31
MET P08581 1/20 0.31
PDGFRA P16234 1/20 0.31
PRKACA P17612 1/20 0.31
LTK P29376 1/20 0.31
GRK5 P34947 1/20 0.31
KDR P35968 1/20 0.31
MAPK8 P45983 1/20 0.31
MAPK9 P45984 1/20 0.31
CSNK1A1 P48729 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23930845 0.83 GPR35 (0.33)
SCHEMBL21879898 0.81 NPSR1 (0.34) NPSR1KDM4EDAPK3JAK2PRKD3
SCHEMBL15071850 0.79 NPSR1 (0.41) NPSR1CYP1A2CYP2C19KDM4EDAPK3
SCHEMBL21879873 0.70 KRAS (0.30)
SCHEMBL21880088 0.69 NPSR1 (0.39) NPSR1CYP1A2CYP2C19KDM4EDAPK3
SCHEMBL21879924 0.69 NPSR1 (0.35) NPSR1KDM4EDAPK3JAK2PRKD3
SCHEMBL21879989 0.67 NPSR1 (0.50) NPSR1KDM4EDAPK3JAK2PRKD3
SCHEMBL21879927 0.67 NPSR1 (0.36) NPSR1CYP1A2CYP2C19KDM4EDAPK3
SCHEMBL23422043 0.66 SMN1; SMN2 (0.40) NPSR1KDM4E
SCHEMBL23421998 0.66 SMN1; SMN2 (0.45) NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021215545-A1 ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-10-28 WO disclosed